Trial reportFrontiers in nutrition2025
Correlation between plasmacytoid dendritic cell activation and suppression of subjective physical symptoms following
Trial report in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study examined the relationship between physical condition and plasmacytoid dendritic cell (pDC) activation in healthy adults who ingested Methods: This randomized, double-blind, placebo-controlled, parallel-group comparative study involved 200 participants who were randomly divided into the LG2055 and placebo groups. The participants ingested one bottle of drinkable yogurt with or without LG2055 daily for 12 weeks. A daily physical health questionnaire on local and systemic symptoms of the common cold was used as the primary outcome. The secondary outcomes were pDC activity, pDC frequency, and IFN-α production by peripheral blood mononuclear cells. Results: Of the 200 participants, 196 completed the intake, and after excluding 8 participants, 188 (95 in the LG2055 group and 93 in the placebo group) were analyzed. The LG2055 group showed a significantly lower ratio of "with symptoms" during the intake period for nine symptoms (nasal congestion, sneezing, hoarseness, cough, headache, general malaise, chills, feverishness, and feeling unwell) (Chi-squared test, Conclusion: The study results indicate that pDC activation by LG2055 contributes to the maintenance of physical condition and suggests that LG2055 improves subjective symptoms by activating pDCs. Clinical trial registration: https://www.umin.ac.jp/ctr/index.htm, identifier UMIN000055950.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.